title: Invited commentary.
authors.affiliation: Department of Hematology, Yale School of Medicine, 333 Cedar St, PO Box 208035, New Haven, CT 06520-8035, USA. henry.rinder@yale.edu
authors.forename: Henry
authors.initials: H
authors.lastname: Rinder
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D002315:Cardiopulmonary Bypass / Q000009:adverse effects*; D001026:Coronary Artery Bypass / Q000009:adverse effects*; D006801:Humans; D009203:Myocardial Infarction / Q000517:prevention & control*; D057127:Single-Chain Antibodies
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D057127:Single-Chain Antibodies; C402724:pexelizumab